Please Wait
Applying Filters...
menu
    • menu
    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-05-19

    Virtual Booth

    An Enquiry

    Chirogate is a professional Prostaglandin manufacturer.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Blarcamesine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Anavex Life Sciences Reports Positive 4-Year Blarcamesine Results
    Anavex Life Sciences Reports Positive 4-Year Blarcamesine Results

    05 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/05/3056284/29248/en/Anavex-Life-Sciences-Announces-Positive-up-to-4-Years-Oral-Blarcamesine-Results-from-Phase-IIb-III-Open-Label-Extension-Trial-in-Early-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    05 Apr 2025
    Share Share
    Anavex Expands IP With Blarcamesin U.S. Patent Issuance
    Anavex Expands IP With Blarcamesin U.S. Patent Issuance

    27 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/27/3015498/29248/en/Anavex-Life-Sciences-Announces-Issuance-of-Blarcamesine-ANAVEX-2-73-Composition-of-Matter-U-S-Patent-Expanding-its-Intellectual-Property-Portfolio.html

    GLOBENEWSWIRE
    27 Jan 2025
    Share Share
    Anavex's Alzheimer Treatment Result Published In Journal
    Anavex's Alzheimer Treatment Result Published In Journal

    15 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/15/3009934/29248/en/Anavex-Life-Sciences-Announces-Peer-Reviewed-Publication-of-Oral-Blarcamesine-Phase-IIb-III-Data-in-The-Journal-of-Prevention-of-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    15 Jan 2025
    Share Share
    Blarcamesine Receives EMA Filing Acceptance for Alzheimer’s Disease
    Blarcamesine Receives EMA Filing Acceptance for Alzheimer’s Disease

    23 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/23/3001118/29248/en/Blarcamesine-Receives-EMA-Filing-Acceptance-for-Treatment-of-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    23 Dec 2024
    Share Share
    Anavex to Report Blarcamesine Phase IIb/III Alzheimer’s Data
    Anavex to Report Blarcamesine Phase IIb/III Alzheimer’s Data

    09 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/09/2993663/29248/en/Anavex-Life-Sciences-to-Report-New-Long-Term-Oral-Blarcamesine-Phase-IIb-III-Alzheimer-s-Disease-Data-at-J-P-Morgan-2025-Healthcare-Conference.html

    GLOBENEWSWIRE
    09 Dec 2024
    Share Share
    Anavex Life's Acceptance of Blarcamesine Phase IIb/III Data Manuscript
    Anavex Life's Acceptance of Blarcamesine Phase IIb/III Data Manuscript

    25 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/25/2986572/29248/en/Anavex-Life-Sciences-Announces-Acceptance-of-Peer-Reviewed-Manuscript-of-Oral-Blarcamesine-Phase-IIb-III-Data-in-a-Reference-Alzheimer-s-Disease-Journal.html

    GLOBENEWSWIRE
    25 Nov 2024
    Share Share